Adjuvant endocrine therapy side-effects among postmenopausal breast cancer patients in Malaysia

References

• Ministry of Health Malaysia. National Cancer Registry Report Malaysia Cancer Statistics – Data and Figure 2007. Putrajaya: Ministry of Health Malaysia; 2011
   Google Scholar
• Cuzick J, Sestak I, Baum M, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 2010;11:1135–41
   PubMed Web of Science ®Google Scholar
• E. B. C. T. C. G. Early Breast Cancer Trialists’ Collaborative Group: Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998;351:1451–67
   PubMed Web of Science ®Google Scholar
• Gaillard S, Stearns V. Aromatase inhibitor-associated bone and musculoskeletal effects: new evidence defining etiology and strategies for management. Breast Cancer Res 2011;13:205
   PubMed Web of Science ®Google Scholar
• Monnier A. Clinical management of adverse events in adjuvant therapy for hormone-responsive early breast cancer. Ann Oncol 2007;18:viii36–44
   PubMed Web of Science ®Google Scholar
• Fallowfield L, Kilburn L, Langridge C, et al. Long-term assessment of quality of life in the Intergroup Exemestane Study: 5 years post-randomisation. Br J Cancer 2012;106:1062–7
   PubMed Web of Science ®Google Scholar
• Morales L, Neven P, Timmerman D, et al. Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients. Anti-Cancer Drugs 2004;15:753–60
   PubMed Web of Science ®Google Scholar
• Kyvernitakis I, Ziller V, Hars O, et al. Prevalence of menopausal symptoms and their influence on adherence in women with breast cancer. Climacteric 2013;17:252–9
   PubMed Web of Science ®Google Scholar
• Garreau J, DeLaMelena T, Walts D, Karamlao K, Johnson N. Side effects of aromatase inhibitors versus tamoxifen: the patients' perspective. Am J Surg 2006;192:496–8
   PubMed Web of Science ®Google Scholar
• Chin S, Trinkaus M, Simmons C, et al. The prevalence and severity of urogenital symptoms in postmenopausal women receiving endocrine therapy for breast cancer. JCO 2008;26:20551
   Web of Science ®Google Scholar
• Whelan TJ, Goss PE, Ingle JN, et al. Assessment of quality of life (QOL) in MA.17, a randomized placebo-controlled trial of letrozole in postmenopausal women following five years of tamoxifen. J Clin Oncol 2005;22:517–517
   Google Scholar
• Cella D, Fallowfield L, Barker P, et al. Quality of life of postmenopausal women in the ATAC (“Arimidex”, tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for early breast cancer. Breast Cancer Res Treat 2006;100:273–84
   PubMed Web of Science ®Google Scholar
• Sestak I, Cuzick J, Sapunar F, et al. Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis. Lancet Oncol 2008;9:866–72
   PubMed Web of Science ®Google Scholar
• Coates A, Keshaviah A, Thürlimann B, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 2007;25:486–92
   PubMed Web of Science ®Google Scholar
• Perez E. Safety profiles of tamoxifen and the aromatase inhibitors in adjuvant therapy of hormone-responsive early breast cancer. Ann Oncol 2007;18:viii26–viii35
   PubMed Web of Science ®Google Scholar
• Høegh-Andersen P, Tankó L, Andersen T, et al. Ovariectomized rats as a model of postmenopausal osteoarthritis: validation and application. Arthritis Res Ther 2004;6:R169
   PubMed Web of Science ®Google Scholar
• Whelan T, Pritchard K. Managing patients on endocrine therapy: focus on quality-of-life issues. Clin Cancer Res 2006;12:1056s–1060s
   PubMed Web of Science ®Google Scholar
• Simon R, Latreille J, Matte C, Desjardins P, Bergeron E. Adherence to adjuvant endocrine therapy in estrogen receptor-positive breast cancer patients with regular follow-up. Can J Surg 2014;57:26–32
   PubMed Web of Science ®Google Scholar
• Baumgart J, Nilsson K, Evers A, Kallak TK, Poromaa IS. Sexual dysfunction in women on adjuvant endocrine therapy after breast cancer. Menopause 2013;20:162–8
   PubMed Web of Science ®Google Scholar
• Egawa C, Hirokaga K, Takao S, et al. Risk factors for joint symptoms in postmenopausal Japanese breast cancer patients treated with anastrozole: a prospective multicenter cohort study of patient-reported outcomes. Int J Clin Oncol 2016;21:262–9
   PubMed Web of Science ®Google Scholar
• Crew K, Greenlee H, Capodice J, et al. Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol 2007;25:3877–83
   PubMed Web of Science ®Google Scholar
• Haines CJ, Xing SM, Park KH, Holinka CF, Ausmanas MK. Prevalence of menopausal symptoms in different ethnic groups of Asian women and responsiveness to therapy with three doses of conjugated estrogens/medroxyprogesterone acetate: The Pan-Asia menopause (PAM) study. Maturitas 2005;52:264–76
   PubMed Web of Science ®Google Scholar
• Calhoun C, Helzlsouer K, Gallicchio L. Racial differences in depressive symptoms and self-rated health among breast cancer survivors on aromatase inhibitor therapy. J Psychosocial Oncol 2015;33:263–77
   PubMed Web of Science ®Google Scholar
• Heinemann K, Ruebig A, Potthoff P, et al. The Menopause Rating Scale (MRS) scale: A methodological review. Health Qual Life Outcomes 2004;2:45
   PubMedGoogle Scholar
• Gupta P, Sturdee DW, Palin SL, et al. Menopausal symptoms in women treated for breast cancer: the prevalence and severity of symptoms and their perceived effects on quality of life. Climacteric 2006;9:49–58
   PubMed Web of Science ®Google Scholar
• Mourits M, Böckermann I, de Vries E, et al. Tamoxifen effects on subjective and psychosexual well-being, in a randomised breast cancer study comparing high-dose and standard-dose chemotherapy. Br J Cancer 2002;86:1546–50
   PubMed Web of Science ®Google Scholar
• Elliott J, Berman H, Kim S. A critical ethnography of Korean Canadian women's menopause experience. Health Care Women Int 2002;23:377–88
   PubMedGoogle Scholar
• Ramoso-Jalbuena J. Climacteric Filipino women: a preliminary survey in the Philippines. Maturitas 1994;19:183–90
   PubMed Web of Science ®Google Scholar
• Rahman S, Zainudin S, Mun V. Assessment of menopausal symptoms using modified Menopause Rating Scale (MRS) among middle age women in Kuching, Sarawak, Malaysia. Asia Pac Fam Med 2010;9:5
   PubMedGoogle Scholar
• Xu L, Wang J, Xue D, He W. Aromatase inhibitors associated musculoskeletal disorders and bone fractures in postmenopausal breast cancer patients: a result from Chinese population. Med Oncol 2014;31:128
   PubMed Web of Science ®Google Scholar
• Okishiro M, Taguchi T, Kim SJ, et al. Incidence of joint symptoms and bone fractures in Japanese postmenopausal breast cancer patients treated with adjuvant anastrozole. J Cancer Res Clin Oncol 2009;135:823–7
   PubMed Web of Science ®Google Scholar
• Park JY, Lee SK, Bae SY, et al. Aromatase inhibitor-associated musculoskeletal symptoms: incidence and associated factors. J Korean Surg Soc 2013;85:205
   PubMedGoogle Scholar
• Ma CX, Adjei AA, Salavaggione OE, et al. Human aromatase: gene resequencing and functional genomics. Cancer Res 2005;65:11071–82
   PubMed Web of Science ®Google Scholar
• Carpenter J, Andrykowski M, Cordova M, et al. Hot flashes in postmenopausal women treated for breast carcinoma: prevalence, severity, correlates, management, and relation to quality of life. Cancer 1998;82:1682–91
   PubMed Web of Science ®Google Scholar
• Savard J, Simard S, Blanchet J, Ivers H, Morin C. Prevalence, clinical characteristics, and risk factors for insomnia in the context of breast cancer. Sleep 2001;24:583–90
   PubMed Web of Science ®Google Scholar
• Kim SH, Son BH, Hwang SY, et al. Fatigue and depression in disease-free breast cancer survivors: prevalence, correlates, and association with quality of life. J Pain Symptom Manage 2008;35:644–55
   PubMed Web of Science ®Google Scholar
• Politi M, Schleinitz M, Col N. Revisiting the duration of vasomotor symptoms of menopause: a meta-analysis. J Gen Intern Med 2008;23:1507–13
   PubMed Web of Science ®Google Scholar
• Mao J, Stricker C, Bruner D, et al. Patterns and risk factors associated with aromatase inhibitor-related arthralgia among breast cancer survivors. Cancer 2009;115:3631–9
   PubMed Web of Science ®Google Scholar
• Dutertre M, Smith C. Molecular mechanisms of selective estrogen receptor modulator (SERM) action. J Pharmacol Exp Therapeutic 2000;295:431–7
   PubMed Web of Science ®Google Scholar